Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Nanomedicine. 2015 Aug 15;11(8):1925–1938. doi: 10.1016/j.nano.2015.07.012

Figure 4. Cremophor-EL induces synthesis of the IL-8 protein de novo from pre-existing IL-8 mRNA.

Figure 4

(A) Human PBMCs were treated with Taxol®, Abraxane®, or Cremophor-EL in the presence or absence of 5 μg/mL of protein synthesis inhibitor CHX. Supernatants were collected after 20 h of incubation and tested for the presence of IL-8 by ELISA. Shown is the mean response (N=2, %CV<20) from one donor; similar results were obtained from two more donors (Supplementary Figure 4A and B). (B) Northern blot analysis. PBMCs were left untreated or incubated with Cremophor-EL or the positive control (PC) for 4 h. The PC is 20 ng/mL of the LPS; Taxol® and Abraxane® were analyzed at equivalent paclitaxel concentrations of 25 μM; the concentration of Cremophor-EL used in this experiment was equivalent to what was used in Taxol® at 25 μM of paclitaxel. Shown is the representative data from one of three tested donors.